Company intelligence / Profile preview
sterna biologicals
Planegg/Martinsried, Bavaria, Germanysterna-biologicals.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Sterna biologicals has completed several Phase IIa clinical trials with its topical DNAzyme-based therapeutic hgd40 targeting GATA‑3. The approach has shown promise as a first-in-class, non-steroidal anti-inflammatory therapy for various chronic inflammatory diseases where current treatments are inadequate or have significant side effects.
- Therapeutic areas
- GastroenterologyPulmonologyDermatologyImmunology
- Modalities
- DNAzyme-based therapeuticsAntisense oligonucleotides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on sterna biologicals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sterna biologicals.